IRCT20200105046010N7 IRCT 2020-08-02 Tabriz University of Medical Sciences Bioequivalence study of manufactured by Esmoprazole 40mg Cap. Kooshan Pharmed. Co. (Eosoflux) in Iranian healthy volunteers In- Vivo Bioequivalence study of Esmoprazole 40mg Cap. Kooshan Pharmed. Co. (Eosoflux) with brand drugs (Nexium® 40mg Cap., AstraZeneca, UK) in Iranian healthy volunteers. 2020-09-19 anticipated 24 Complete https://irct.ir/trial/48034 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Other design features: Tow period / Tow sequence with a washout time, Randomization description: People in different age groups are invited to collaborate through the advertisement. Then people are selected and individuals in each group randomly selected from the qualified people to participate in the project. The first twelve are considered as (first sequence: Eosoflux recipient) and the second twelve are considered as (second sequence:Nexium® 40mg recipient), Blinding description: This study is a blind side clinical trial (volunteers). Eosoflux and Nexium® are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form. Bioequivalence In this study the bioequivalence of test and brand of Glorenta® will evaluated.. Intervention 1: Intervention group1: Single dose of 40 mg Esomeprazole capsule (Nexium 40mg Cap., Astra-Zeneca, UK)Pharmaceutical Company as a reference product. Intervention 2: Intervention group2:Single dose of 40 mg Esomeprazole tablet by Koushan-Pharmed Pharmaceutical Company as a test product. No - There is not a plan to make this available Justification or reason for not sharing IPD is These date are as secure between researcher and related industries.